Metastatic Renal Cell Cancer: Summary from ASCO 2015

Editorial, CUAJ

doi:10.5489/cuaj.3212

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nearly 10 different platinum-based therapies are suggestedto treat recurrent ovarian cancer patients following more than 6 months from first-line treatment (platinum-sensitive recurrent disease), and more than 20 different therapies (mostly single agents) for treatment of patients who recurr within 6 months following first-line treatment (platinum-resistant recurrent disease) [ 44 ] and treatment choices are made empirically [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer

Howard

Bush

Zgheib

et al. 2021

SRDT

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer

Howard

Bush

Zgheib

et al. 2021

SRDT

View full text Add to dashboard Cite

show abstract

“…The CheckMate016 phase I trial included patients with mRCC and was first presented at ASCO 2015. This study demonstrated that a combination of nivolumab and ipilimumab exhibited a durable antitumor effect with a manageable safety profile [ 70 ]. A recently reported 5-year follow-up investigation of the phase I participants revealed a 34% 5-year survival rate for mRCC patients whom failed prior anti-angiogenesis therapy and then placed on maintenance nivolumab [ 71 ].…”

Section: Paradigm Shift In the Treatment Of Mrcc After Anti-angiogenementioning

confidence: 99%

New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy

Zarrabi

Fang

2017

J Hematol Oncol

View full text Add to dashboard Cite

Angiogenesis is a critical process in the progression of advanced renal cell carcinoma. Agents targeting angiogenesis have played a primary role in the treatment of metastatic renal cell carcinoma. However, resistance to anti-angiogenesis therapy almost always occurs, and major progress has been made in understanding its underlying molecular mechanism. Axitinib and everolimus have been used extensively in patients whom have had disease progression after prior anti-angiogenesis therapy. Recently, several new agents have been shown to improve overall survival in comparison with everolimus. This review provides an in-depth summary of drugs employable in the clinical setting, the rationale to their use, and the studies conducted leading to their approval for use and provides perspective on the paradigm shift in the treatment of renal cell carcinoma. Highlighted are the newly approved agents cabozantinib, nivolumab, and lenvatinib for advanced renal cell carcinoma patients treated with prior anti-angiogenesis therapy.

show abstract

Immunotherapy for Prostate Cancer: An Evolving Landscape

Mao

Drake

2017

Oncoimmunology

View full text Add to dashboard Cite

Metastatic Renal Cell Cancer: Summary from ASCO 2015

Cited by 3 publications

References 11 publications

Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer

Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer

New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy

Immunotherapy for Prostate Cancer: An Evolving Landscape

Contact Info

Product

Resources

About